Novel biomarker algorithmic panel measuring permutations of immune response to cardiac endothelial injury and global risk factors identifies patients at risk of acute coronary syndrome (ACS)
Serum sLOX-1 concentrations are associated with 2- year major adverse cardiovascular and cerebrovascular events in patients after percutaneous coronary intervention: A multicenter pilot study